Cargando…

Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.

Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Volm, M., Koomägi, R., Mattern, J., Stammler, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223613/
https://www.ncbi.nlm.nih.gov/pubmed/9192980
_version_ 1782149431313825792
author Volm, M.
Koomägi, R.
Mattern, J.
Stammler, G.
author_facet Volm, M.
Koomägi, R.
Mattern, J.
Stammler, G.
author_sort Volm, M.
collection PubMed
description Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks, P = 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08) and an inverse relationship between cyclin A and the proportion of G0/G1-phase cells (P = 0.04) were found. Furthermore, a significant correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P = 0.026). IMAGES:
format Text
id pubmed-2223613
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22236132009-09-10 Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Volm, M. Koomägi, R. Mattern, J. Stammler, G. Br J Cancer Research Article Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks, P = 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08) and an inverse relationship between cyclin A and the proportion of G0/G1-phase cells (P = 0.04) were found. Furthermore, a significant correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P = 0.026). IMAGES: Nature Publishing Group 1997 /pmc/articles/PMC2223613/ /pubmed/9192980 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Volm, M.
Koomägi, R.
Mattern, J.
Stammler, G.
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title_full Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title_fullStr Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title_full_unstemmed Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title_short Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
title_sort cyclin a is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223613/
https://www.ncbi.nlm.nih.gov/pubmed/9192980
work_keys_str_mv AT volmm cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas
AT koomagir cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas
AT matternj cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas
AT stammlerg cyclinaisassociatedwithanunfavourableoutcomeinpatientswithnonsmallcelllungcarcinomas